Stendra
(Avanafil)ApprovedSmall molecule
Avanafil is used to treat erectile dysfunction (impotence) in men. It works by increasing blood flow to the penis to help achieve and maintain an erection during sexual activity.[2] Stendra is currently approved and in use across 3 indications[4].[1]
Stendra is one of 74 small molecule programs targeting Erectile Dysfunction. It is currently in Approved.
3
Indications
20
Total Trials
0
Active Trials
73
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
245 competitors in Kidney Disease
#DrugCompanyPhaseTrials
1Stendra
VVIVUS LLC
Approved
Invirase
RochePhase 3
Evrenzo
AstellasPhase 3
Edarbi
TakedaPhase 3
Zemplar
AbbViePhase 3
Reata
BiogenPhase 3
Victoza
Novo NordiskPhase 3
Myfortic
NovartisPhase 3
Aranesp
AmgenPhase 3
Gazyva
RochePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Erectile Dysfunction8 trials
Show 5 more trials
Tics2 trials
Interaction2 trials
Efficacy and Safety1 trial
Oral1 trial
4 more indications
Renal Impairment1 trial
Regulatory
FDA Approval Timeline[5]
Apr 27, 2012
STENDRA
NDA NDA202276
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Stendra drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Avanafil. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]